The Alliance for Regenerative Medicine is the international advocacy organisation representing the cell and gene therapy and broader advanced therapies sector.

 

Background

  • ARM published a Therapeutic Developers’ Statement of Principles, a bioethical framework for the use of gene editing in therapeutic applications signed by 13 biotech companies
  • This was the first time that companies operating in the industry have formally agreed principles to adhere to in this highly innovative area
  • Publication coincided with address by ARM CEO Janet Lambert to a World Health Organization meeting

 

Consilium’s Strategy

  • Placed with Financial Times science editor, under embargo, who interviewed Janet Lambert and Jim Burns, Chief Executive of Casebia Therapeutics
  • Broad outreach to European trade and newswire media on day of announcement

 

Outcome

  • Financial Times piece published online and in print on the day of announcement
  • Story was featured as a leader piece in the FT and in the Lex Column on business and finance
  • Extensive media coverage across trade and newswire press including key targets at BioCentury, BioWorld and Endpoints
  • Coverage led to requests from multiple outlets for opinion pieces by Janet Lambert on gene editing